

All Your Ingredients In One Magazine

Ingredients

SOUTH ASIA

19TH Anniversary

A Saffron Media Publication
Vol. 20, Issue 2, Pages-44



LUX FLAVOURS

ISO 9001:2008 & 14001 : 2004 CERTIFIED COMPANY
CHENNAI

PLANT I

MANUFACTURES OF FLAVOURING ESSENCES FOR

BISCUITS, CONFECTIONERIES, BAKERIES,

PHARMACEUTICALS

AERATED WATERS AND LIQUORS

PLANT II

SPRAY DRYER

(LIQUID TO POWDER)

PHARMACEUTICAL

MANUFACTURERS OF PHARMACEUTICAL FORMULATIONS
(UNDER BRAND NAME OF KAUSIKH)

OFFICE:

NEW No.21, DURAIRAJ STREET

PALAVANTHANGAL

CHENNAI - 600 114

PHONE: 22671018 / 22671984

FAX : 22672904

E MAIL : luxflavours@dataone.in, info@luxflavours.com

WEBSITE: www.luxflavours.com

FACTORY:


PLOT No.3,4,6,7 KUNRATHUR HIGH ROAD

GERUGAMBAKKAM

CHENNAI - 600 122

TELEFAX: 2382 0045 / 2382 0680

2382 0833 / 2382 0844



CAPEX boosts Indian API industry

DR. SANJAY AGARWAL

CAPITAL expenditure (CAPEX) is emerging as a critical driver of growth and transformation in India's Active Pharmaceutical Ingredients (API) industry. As pharmaceutical companies seek to strengthen domestic manufacturing, reduce dependence on imported raw materials, improve operational efficiency and meet evolving global quality standards, investments in manufacturing infrastructure and technology are becoming increasingly important.

APIs are the active components responsible for the therapeutic effect of medicines. Their production requires specialised facilities, sophisticated equipment, stringent quality controls and compliance with regulatory requirements. Consequently, capital investment decisions in the API segment directly influence production capacity, cost competitiveness, supply chain resilience and long-term profitability.

India's established pharmaceutical manufacturing base, skilled workforce and growing focus on self-reliance provide a strong foundation for further investment. However, the direction and effectiveness of CAPEX will determine how successfully the country strengthens its position in the global API supply chain.

Understanding CAPEX in API Industry

In the pharmaceutical sector, CAPEX refers to expenditure on long-term assets required to manufacture, process, test and store pharmaceutical products. For API manufacturers, this includes establishing new manufacturing facilities, expanding existing plants, modernising equipment, developing research infrastructure and investing in environmental management systems and digital technologies.

API production is particularly capital-intensive because manufacturing processes must meet rigorous standards of consistency, purity, safety and traceability. Depending on the product portfolio, facilities may require specialised reactors, fermentation systems, crystallisation equipment, purification units, solvent recovery systems and advanced analytical laboratories.

CAPEX decisions typically focus on three priorities: capacity expansion, technology modernisation and regulatory compliance. While expansion enables companies to serve growing demand, modernisation improves productivity and product quality. Compliance-related investments help manufacturers meet environmental regulations and domestic and international regulatory requirements. A balanced strategy must address all three priorities rather than focusing exclusively on increasing production volumes.

Key drivers of CAPEX growth in India Reducing import dependence

One of the principal drivers of investment in the Indian API industry is the need to strengthen domestic manufacturing of critical APIs, key starting materials (KSMs) and drug intermediates. Dependence on overseas suppliers for selected products can expose pharmaceutical manufacturers to geopolitical disruptions, logistics bottlenecks, currency fluctuations and sudden price increases.

Investment in domestic production can diversify sourcing, improve supply continuity and create greater control over manufacturing costs. This opportunity is particularly significant for essential pharmaceutical ingredients where supply concentration presents strategic risks. However, import substitution must remain commercially viable. Manufacturers need to evaluate domestic demand, global pricing, input availability and production economics before committing substantial capital.

Government Incentives and industrial infrastructure

Government initiatives have played an important role in encouraging investment in domestic API manufacturing. The Production Linked Incentive (PLI) scheme for critical KSMs, drug intermediates and APIs has an approved financial outlay of Rs. 6,940 crore, supporting efforts to build domestic manufacturing capabilities.

The government has also approved three bulk drug parks in Andhra Pradesh, Gujarat and Himachal Pradesh. These parks are intended to provide common infrastructure, including effluent treatment, utilities, solvent recovery, warehousing and laboratory facilities.

Such infrastructure can reduce the financial burden of developing supporting facilities independently, particularly for manufacturers establishing new production units. Shared infrastructure can also improve resource utilisation and create opportunities for economies of scale.

Nevertheless, incentives and infrastructure support are only part of the investment equation. Timely project execution, efficient commissioning and sustained demand are essential to convert announced investments into productive manufacturing capacity.

Growing pharmaceutical demand

India's pharmaceutical industry serves a substantial domestic market and supplies medicines to international markets. Demand for generic medicines, chronic disease treatments and essential drugs creates opportunities for API manufacturers to expand production and develop specialised capabilities.

As pharmaceutical companies diversify their product portfolios, API manufacturers may need additional production lines, flexible manu-

facturing systems and facilities capable of handling multiple products. Investment opportunities also exist in complex APIs, high-potency ingredients and specialised molecules. These segments require advanced technical capabilities and stringent containment measures but can offer differentiation beyond conventional volume-driven manufacturing.

Major areas of capital investment Greenfield and brownfield projects

Greenfield projects involve establishing new manufacturing facilities, while brownfield projects expand or modernise existing plants. Greenfield investments allow companies to incorporate advanced layouts and technologies from the outset. Brownfield projects, meanwhile, can benefit from existing infrastructure, trained personnel and established customer relationships.

The choice depends on capacity utilisation, land and utility availability, regulatory requirements, project timelines and expected returns. Companies must also account for technology transfer, process validation and the time required to achieve commercial production. A detailed feasibility assessment is essential to ensure that investment decisions align with long-term business objectives.

Technology and process automation

Automation and digitalisation are increasingly important in API manufacturing. Investments in process control systems, real-time monitoring, manufacturing execution systems and advanced analytical technologies can improve consistency, reduce human error and strengthen batch traceability.

Process optimisation can improve yields, shorten production cycles and reduce solvent and energy consumption. These improvements are particularly valuable in cost-sensitive markets, where even modest gains in manufacturing efficiency can influence competitiveness.

For manufacturers targeting regulated international markets, investments in data integrity, electronic documentation and robust quality systems are equally important. Digital capabilities can support better decision-making while strengthening compliance and operational transparency.

Environmental sustainability and compliance

Environmental management is another major component of API-related CAPEX. Chemical manufacturing can generate solvent waste, effluents and other by-products that require appropriate treatment and disposal.

Investment in effluent treatment plants, solvent recovery, waste minimisation and energy-efficient utilities can improve environmental

CONTINUED ON p26▶

Challenges affecting investment decisions

CONTINUED FROM p25 ▶

performance while reducing long-term operating costs. Zero-liquid-discharge systems may also be necessary where applicable regulations or site conditions require them.

Although these investments can increase initial project expenditure, they help mitigate regulatory risks, improve resource efficiency and support sustainable manufacturing practices. Environmental compliance should therefore be incorporated into project planning rather than treated as an additional expense after construction.

Challenges affecting investment decisions

Despite favourable long-term prospects, API manufacturers face several challenges when planning capital expenditure.

High upfront costs: Manufacturing facilities, specialised equipment, utilities and quality infrastructure require substantial initial investment. Smaller companies may encounter difficulties accessing affordable financing.

Long project gestation periods: Construction, equipment installation, validation and regulatory approvals can delay commercial production. Such delays increase financing costs and postpone revenue generation.

Price competition: Domestic manufacturers compete with established international suppliers. Lower production costs and large-scale manufacturing elsewhere can place pressure on margins, particularly for commoditised APIs.

Regulatory complexity: Different markets have distinct regulatory expectations. Maintaining compliance requires continuous investment in quality systems, documentation, inspections and facility upgrades.

Demand uncertainty: Capacity expansion without sufficient customer commitments can result in underutilised assets. This risk is particularly significant when companies invest in

specialised products with uncertain demand.

These challenges highlight the importance of disciplined capital allocation, realistic demand forecasting and careful project evaluation.

Strategic priorities for API manufacturers

To maximise returns on CAPEX, Indian API manufacturers should adopt a long-term, risk-adjusted investment approach.

First, companies should prioritise products with sustainable demand, supply-chain significance and attractive manufacturing economics. Market intelligence and customer engagement can help identify opportunities before substantial capital is committed.

Second, manufacturers should evaluate total lifecycle costs rather than focusing solely on initial construction expenditure. Energy efficiency, maintenance, waste treatment, labour productivity and compliance costs can significantly affect long-term profitability.

Third, phased investments can help manage risk. Companies may expand production capacity in stages, align equipment purchases with demand visibility and establish customer relationships before commissioning additional lines.

Finally, investment decisions should incorporate resilience and sustainability. Reliable utilities, diversified sourcing of critical inputs, process efficiency and environmental safeguards can reduce operational vulnerabilities throughout an asset's lifecycle.

Outlook: From capacity expansion to competitiveness

The future of CAPEX in India's API industry will depend not merely on the amount invested, but on the productivity and strategic value of that investment. Government support, domestic demand and supply-chain diversification provide a favourable foundation for growth. At the

same time, international competition and stringent quality requirements will demand continuous improvements in manufacturing efficiency and reliability.

Investment in advanced technologies, specialised products, environmental infrastructure and skilled personnel can help Indian manufacturers move beyond basic capacity expansion towards higher-value production. Bulk drug parks may further support this transition by improving access to shared infrastructure and reducing the cost burden on individual manufacturers.

The next phase of industry growth will require closer alignment between investment plans, market demand, technological capabilities and regulatory readiness. Companies that combine efficient capital deployment with innovation and operational excellence will be better positioned to compete in global markets.

Conclusion

CAPEX is a strategic lever for strengthening India's API manufacturing ecosystem. Investments in new facilities, process modernisation, automation and environmental compliance can improve supply security, operational efficiency and global competitiveness.

However, sustainable growth requires more than building additional capacity. Manufacturers must ensure that capital is directed towards commercially viable products, efficient processes and robust quality systems.

As India continues to strengthen its pharmaceutical manufacturing capabilities, disciplined and strategically directed CAPEX can help establish a more resilient, technologically advanced and globally competitive API industry. ○

(The author is pharmaceutical consultant)